Ally Bridge Group (NY) LLC — 13F Holdings & Portfolio

CIK 1822947 · latest 13F-HR filed 2026-08-14

Ally Bridge Group (NY) LLC manages $113.1M in 13F-reported U.S. long-equity assets across 25 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are DFTX (16.64%), ABVX (14.73%), NERV (10.68%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 10 new positions and exited 8; 4 existing positions rose in reported value and 9 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$113.1M

Long-equity book

Holdings
25

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+10 / −8 / ↑4 / ↓9

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 64.8%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Assets Under Management
$218.9M
Discretionary
$218.9M
Employees
7
Accounts
3
Address
430 PARK AVENUE
12TH FLOOR
NEW YORK, NY 10022
Phone
(646) 829-9373
Name Title / Status Ownership Type
ABG MANAGEMENT LTD ControlSHAREHOLDER
since Mar 2017
75% or moreForeign Entity
ALEX, SLANIX PAUL, T ControlPRESIDENT & PORTFOLIO MANAGER
since Jan 2023
Less than 5%Individual
BENDETSON, MICHAEL, NOVICK ControlCOO, HEAD OF LEGAL & CHIEF COMPLIANCE OFFICER
since Feb 2021
Less than 5%Individual
CORB, KEVIN, WILLIAM ControlCHIEF FINANCIAL OFFICER
since Feb 2023
Less than 5%Individual
YU, FAN Control
Indirect owner via ABG MANAGEMENT LTD
SHAREHOLDER AND DIRECTOR
since Jun 2013
75% or moreIndividual
Ownership & leadership changes · 4 filings with changes since Jun 30, 2021

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 28, 2024 filing
  • ChangedALEX, SLANIX PAUL, T · title PORTFOLIO MANAGER → PRESIDENT & PORTFOLIO MANAGER
Feb 15, 2023 filing
  • No longer listedJOHNSON, DANIEL, JOHN · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Jul 2020
  • No longer listedSIMEONIDIS, SIMOS, EFTHYMIOS · PRESIDENT AND PORTFOLIO MANAGER · Less than 5% · control person · listed since Jul 2022
  • AddedALEX, SLANIX PAUL, T · PORTFOLIO MANAGER · Less than 5% · control person
  • AddedCORB, KEVIN, WILLIAM · CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • ChangedBENDETSON, MICHAEL, NOVICK · title HEAD OF LEGAL & CHIEF COMPLIANCE OFFICER → COO, HEAD OF LEGAL & CHIEF COMPLIANCE OFFICER
Jul 27, 2022 filing
  • No longer listedYAEGER, ANNA, COSSLETT · PORTFOLIO MANAGER AND PRESIDENT · Less than 5% · control person · listed since Jul 2017
  • AddedSIMEONIDIS, SIMOS, EFTHYMIOS · PRESIDENT AND PORTFOLIO MANAGER · Less than 5% · control person
Mar 29, 2022 filing
  • ChangedBENDETSON, MICHAEL, NOVICK · title DIRECTOR OF LEGAL & COMPLIANCE, CHIEF COMPLIANCE OFFICER → HEAD OF LEGAL & CHIEF COMPLIANCE OFFICER
Jun 30, 2021 filing (earliest on record)
  • ListedABG MANAGEMENT LTD · SHAREHOLDER · 75% or more · control person
  • ListedBENDETSON, MICHAEL, NOVICK · DIRECTOR OF LEGAL & COMPLIANCE, CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ListedJOHNSON, DANIEL, JOHN · CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • ListedYAEGER, ANNA, COSSLETT · PORTFOLIO MANAGER AND PRESIDENT · Less than 5% · control person
  • ListedYU, FAN · SHAREHOLDER AND DIRECTOR · 75% or more · indirect via ABG MANAGEMENT LTD · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Ally Bridge Group (NY) LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 DEFINIUM THERAPEUTICS INC Call DFTX 24477V105 $18.8M 16.64% 400,000 SH
2 ABIVAX SA Call ABVX 00370M103 $16.7M 14.73% 125,000 SH
3 MINERVA NEUROSCIENCES INC NERV 603380205 $12.1M 10.68% 2,175,802 SH
4 PROMIS NEUROSCIENCES INC PMN 74346M505 $8.2M 7.22% 620,319 SH
5 FIRST TRACKS BIOTHERAPEUTICS TRAX 337185102 $5.7M 5.06% 284,287 SH
6 AXSOME THERAPEUTICS INC AXSM 05464T104 $4.0M 3.57% 16,493 SH
7 ASSEMBLY BIOSCIENCES INC ASMB 045396207 $3.8M 3.40% 140,000 SH
8 WHITEHAWK THERAPEUTICS INC WHWK 00032Q104 $3.7M 3.31% 817,939 SH
9 EDGEWISE THERAPEUTICS INC EWTX 28036F105 $3.4M 2.99% 83,300 SH
10 CLIMB BIO INC CLYM 28658R106 $3.2M 2.87% 249,172 SH
11 KURA ONCOLOGY INC KURA 50127T109 $3.2M 2.81% 290,000 SH
12 CYTOMX THERAPEUTICS INC. CTMX 23284F105 $2.9M 2.57% 775,000 SH
13 AVALO THERAPEUTICS INC AVTX 05338F306 $2.8M 2.45% 150,000 SH
14 PALISADE BIO INC PALI 696389402 $2.6M 2.27% 1,229,000 SH
15 SOLID BIOSCIENCES INC SLDB 83422E204 $2.6M 2.26% 255,959 SH
16 AN2 THERAPEUTICS INC ANTX 037326105 $2.5M 2.25% 526,315 SH
17 UROGEN PHARMA LTD URGN M96088105 $2.5M 2.25% 69,183 SH
18 PERSPECTIVE THERAPEUTICS INC CATX 46489V302 $2.5M 2.24% 743,958 SH
19 IDEAYA BIOSCIENCES INC IDYA 45166A102 $2.5M 2.22% 67,500 SH
20 INVENTIVA SA IVA 46124U107 $2.4M 2.12% 634,800 SH
21 ALUMIS INC ALMS 022307102 $2.2M 1.90% 76,459 SH
22 OVID THERAPEUTICS INC OVID 690469101 $1.7M 1.49% 624,561 SH
23 EUPRAXIA PHARMACEUTICALS INC EPRX 29842P105 $1.7M 1.47% 252,175 SH
24 IBIO INC IBIO 451033708 $682.8K 0.60% 390,147 SH
25 TRAWS PHARMA INC TRAW 68232V884 $663.0K 0.59% 786,236 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $113.1M 25 0001193125-26-352338
2026-03-31 2026-05-18 $123.8M 28 0001193125-26-227559
2025-12-31 2026-02-17 $96.0M 20 0001193125-26-055035
2025-09-30 2025-11-14 $164.2M 25 0001193125-25-283054
Filer Information
Address
430 PARK AVENUE, 12TH FLOOR
NEW YORK, NY 10022
Phone
(646) 829-9830
Filing Manager
Ally Bridge Group (NY) LLC
NEW YORK, NY
Signatory
Fan Yu
Director